

## CVS Health/Aetna updates Pharmacy Clinical Policy Bulletins: Weight Loss Management - Wegovy

Plans : Aetna Non-Medicare Prescription Drug Plan



### Subject: Wegovy PA Policy 4774-A 08-2021

(Refer to above link for complete guidelines on the Policy, Limitations of Use, and Coverage Criteria)

#### Policy highlights

##### FDA-approved Indications

**Wegovy** is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:

- 30 kg/m<sup>2</sup> or greater (obesity), or
- 27 kg/m<sup>2</sup> or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)

##### Limitations of Use:

- **Wegovy** contains semaglutide and should not be coadministered with other semaglutide-containing products or with any other GLP-1 receptor agonist.
- The safety and effectiveness of **Wegovy** in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.
- **Wegovy** has not been studied in patients with a history of pancreatitis

Additional Pharmacy Policy and Formulary information can be found here: <https://www.aetna.com/health-care-professionals/pharmacy-services/pharmacy-management.html>

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

## CVS Health/Aetna updates Pharmacy Clinical Policy Bulletins: Antidiabetic GLP-1 - Ozempic

Plans : Aetna Non-Medicare Prescription Drug Plan



### Subject: GLP-1 Agonist Ozempic PA with Limit Policy 2439-C 08-2022 v2

(Refer to above link for complete guidelines on the Policy, Limitations of Use, and Coverage Criteria)

#### Policy highlights

##### FDA-approved Indications

**Ozempic** is indicated as:

- an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.

##### Limitations of Use:

- **Ozempic** has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- **Ozempic** is not indicated for use in patients with type 1 diabetes mellitus.

Additional Pharmacy Policy and Formulary information can be found here: <https://www.aetna.com/health-care-professionals/pharmacy-services/pharmacy-management.html>

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

# CVS Health/Aetna updates

## Pharmacy Clinical Policy Bulletins: Antidiabetic GLP-1, GIP-GLP-1 Agonist Limit Policy cont..

Plans : Aetna Non-Medicare Prescription Drug Plan

### Subject: Antidiabetic GLP-1, GIP-GLP-1 Agonist Limit Policy 4525-H 08-2022 v2

(Refer to above link for complete guidelines on the Policy, Limitations of Use, and Coverage Criteria)

#### DRUG: GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE

**ADLYXIN** (*lixisenatide*)

**BYDUREON** (*exenatide extended-release*)

**BYDUREON BCISE** (*exenatide extended-release*)

**BYETTA** (*exenatide*)

**MOUNJARO®** (*tirzepatide*)

**OZEMPIC** (*semaglutide*)

**RYBELSUS** (*semaglutide*)

**TRULICITY** (*dulaglutide*)

**VICTOZA** (*liraglutide*)

**Additional Pharmacy Policy and Formulary information can be found here:** <https://www.aetna.com/health-care-professionals/pharmacy-services/pharmacy-management.html>

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.